Clinical Trial

A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 9, 2024 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This open-label Phase 1 study will evaluate the safety, tolerability, PK characteristics and preliminarily efficacy of JMKX003948 tablets in patients with renal cell carcinoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-03-14.
Status change: Not Yet Recruiting → Recruiting 2024-07-06
Trial Details
NCT Number NCT06321250
Lead Sponsor Jemincare
Collaborators: Zhejiang Hangyu Pharmaceutical Co., Ltd.
Conditions Renal Cell Carcinoma Metastatic
Enrollment 80 participants
Start Date 2024-03-14
Primary Completion 2026-05-31 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2024-07-09